Ligand id: 5664

Name: cediranib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 72.5
Molecular weight 450.21
XLogP 4
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Cediranib has been assessed in clinical trial as a treatment for several types of malignancies, including non-small cell lung cancer, kidney cancer, colorectal cancer and central nervous system cancer (in children). Whilst several trials have been terminated or have not progressed further, a few are still ongoing (May 2014). Click here to view active trials registered with ClinicalTrials.gov .
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis reduces the vascularisation which underpins and supports tumour development and growth in some cancers.